Project Details
Description
A Randomized Phase II Study of VTX-2337 in Combination with Pegylated Liposomal Doxorubicin (PLD) vs PLD alone in the Treatment of Recurrent or Persi A Randomized Phase II Study of VTX-2337 in Combination with Pegylated Liposomal Doxorubicin (PLD) vs. PLD alone in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 12/1/15 → 11/30/16 |
Funding
- INDUSTRY: Domestic Company: $10,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.